CClinicalTrials.gg
CompletedNCT03196037Updated Mar 7, 2019

Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors

An interventional study of Tai Chi in Cancer, Breast and Cognitive Impairment, sponsored by UNC Lineberger Comprehensive Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Purpose:To gather preliminary data and to determine the feasibility and acceptability of an 8-week Tai Chi intervention for adults cancer survivors (survivors) who report experiencing cognitive impairment, and to perform exploratory analyses to assess improvements in cognitive performance, health-related quality of life, brain activity, and blood-based biomarkers.

Participants: Adult survivors (> 18 years old) who report experiencing cognitive impairment and are within 60 months of completion of chemotherapy for treatment of a breast cancer diagnosis.

Procedures (methods): A single arm pre-/post-test non-randomized study design in adult cancer survivors (Enrollment goal N=15; current age ≥ 18 years, treatment completed within 60 months). Outcomes will be assessed at baseline and after the 8-week Tai Chi intervention, and consist of feasibility, acceptability, expectancy/credibility, health-related quality of life, cognitive performance, serum biomarkers, and brain activity.

Read the detailed description

The objective of this study is to gather preliminary data and to determine the feasibility and acceptability of an 8-week Tai Chi intervention for adults within 60 months of having completed chemotherapy for treatment of a cancer diagnosis who report experiencing cognitive impairment (cancer-related cognitive impairment; CRCI). Tai Chi is a form of physical activity that includes an inherent level of cognitive engagement into its performance. Rodent studies provide evidence that including a cognitive component to physical activity (PA) changes its effect on the brain, with aerobic PA inducing angiogenesis and cognitively engaging PA inducing synaptogenesis. Human research with older adults indicates that interventions that combine PA and cognitive engagement produce greater cognitive benefits than PA alone. Experimental and meta-analytic evidence have shown that participation in PA improves cognitive performance in nonclinical and clinical populations, including breast cancer survivors. Importantly, physical activity benefits the same cognitive domains that are negatively affected by CRCI (i.e., attention/processing, memory, executive function). Recently, meta-analytic evidence showed that PA might benefit CRCI. However, in most studies cognitive outcomes are limited to measures of subjective cognitive function rather than objective measures of performance such as neuropsychological assessments or brain activity (e.g., EEG). Research into the effects of Tai Chi on CRCI is sparse, yet promising.

Additionally, research has shown positive effects from Tai Chi on health-related quality of life and cytokines in cancer survivors. To achieve our objective of examining feasibility and acceptability of an 8-week Tai Chi intervention, we will use a single arm pre-/post-test non-randomized study design in adult breast cancer survivors (Enrollment goal N=15; current age ≥ 18 years, treatment completed within 60 months). Outcomes will be assessed at baseline and after the 8-week Tai Chi intervention, and consist of feasibility, acceptability, expectancy/credibility, health-related quality of life, cognitive performance, serum biomarkers, and brain activity. This feasibility study will help identify barriers to recruitment and retention, determine the acceptability of a 8- week Tai Chi intervention for cancer survivors, and provide data for use in designing subsequent studies. Specifically, the findings will inform the design of a randomized controlled trial (RCT) that is sufficiently powered to examine efficacy. The ultimate goal of this research is to create and test a method of investigation into the use of Tai Chi to prevent or mitigate CRCI as well as a method of improving health-related quality of life in cancer survivors.

02

Conditions studied

  • Cancer, Breast
  • Cognitive Impairment

Browse trials for

03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 4 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 414 studies on the registry; 96 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 25 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Was diagnosed with breast cancer (all stages accepted).
  • Currently > 18 years of age
  • Age at cancer diagnosis > 18 years.
  • Able to engage in moderate intensity exercise as determined by their treating physician. If participant no longer has a treating physician, safety will be determined by following the American College of Sports Medicine (PAR-Q \& YOU) physical activity questionnaire. An answer of "yes" to > one of the seven questions will require the participant to receive written permission from their physician prior to beginning the Tai Chi intervention.
  • Not previously engaged in regular exercise training (>1-2d/wk for >30 min/d) in past 6 months.
  • Completed chemotherapy treatment for a breast cancer diagnosis.
  • Cancer chemotherapy treatment completed within last 60 months. Defined as not currently scheduled for or undergoing active treatment (chemotherapy, radiation, surgery). Treatments to prevent or delay recurrence (e.g., breast cancer hormonal therapies) or for maintenance of remission are allowed.
  • Report experiencing cognitive impairment following treatment for cancer.
  • No psychiatric disorder with psychotic features.
  • Able to receive emails from study staff (i.e. for receiving study reminders).
  • Able to speak and read English.
  • Able to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to complete study procedures.
  • Currently participating in another study which would preclude participation in this study.
  • Has a known additional malignancy that is metastatic, progressing, or requires active treatment.
  • Has a neurocognitive disorder of other etiologies, such as Alzheimer's Parkinson's, etc., that might confound the analysis
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Tai Chi

    The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.

    Behavioral: Tai Chi

Interventions

  • BehavioralTai Chi

    An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).

06

What researchers measure

Primary outcomes

  1. Feasibility - Attendance

    Feasibility will be achieved if we observe at least 80% attendance (i.e., at least 13 out of 16 sessions attended).

    Time frame: post 8-week intervention

  2. Feasibility Pre-Test Completion

    Feasibility will be achieved if we observe at least 80% completion. Completion rates will be the proportion of completed measures (number completed measures/total administered measures at pre-test).

    Time frame: Baseline

  3. Feasibility Post-Test Completion

    Feasibility will be achieved if we observe at least 80% completion. Completion rates will be the proportion of completed measures (number completed measures/total administered measures at post-test).

    Time frame: post 8-week intervention

Secondary outcomes

  1. Recruitment - Frequency Approached for Screening

    We will describe the frequency approached for screening.

    Time frame: Baseline

  2. Recruitment - Proportion of Completed Screening

    We will describe the proportion of completed screening (out of approached for screening)

    Time frame: Baseline

  3. Recruitment - Screened Eligible

    We will describe those screened and found to be eligible (out of total screened).

    Time frame: Baseline

  4. Retention Rate

    We will describe study retention (number who remain enrolled over 8 weeks/total number originally enrolled).

    Time frame: post 8-week intervention

  5. Recruitment - Enrollment Refusal

    We will collect reasons for enrollment refusal (as part of the screening survey)

    Time frame: Baseline

  6. Retention - Withdrawals

    We will collect reasons for study withdrawals.

    Time frame: post 8-week intervention

  7. Feasibility of the Different Recruitment Strategies - Screened

    For each recruitment strategy, we will describe the frequency screened,

    Time frame: Baseline

  8. Feasibility of the Different Recruitment Strategies - Screened Eligible

    For each recruitment strategy, we will describe those screened and found to be eligible (out of total screened).

    Time frame: Baseline

  9. Feasibility of the Different Recruitment Strategies - Enrolled

    For each recruitment strategy, we will describe those enrolled (out of total screened eligible).

    Time frame: Baseline

  10. Expectancy/Credibility

    The Expectancy/Credibility Questionnaire will be used to assess baseline expectancy and credibility effects of taking part in the Tai Chi intervention. Responses to six questions will be indicated with a 1 to 9 Likert-type scale, with higher numbers representing greater expectancy/credibility.

    Time frame: Baseline

  11. Acceptability

    The Intervention Satisfaction Scale questions: 1) "Overall, I really enjoyed the Tai Chi intervention" and 2) "I would recommend the Tai Chi intervention to other cancer survivors" will assess acceptability. Acceptability will be achieved if the mean score is 3 or greater (response range: 0=Strongly disagree to 4=Strongly agree).

    Time frame: post 8-week intervention

  12. Intervention Satisfaction Questionnaire

    Three close-ended questions will use a Likert scale (0= strongly disagree to 4=strongly agree) to assess whether the class length, frequency, and duration was satisfactory. Four open-ended questions will collect information on what participants liked or disliked about the Tai Chi intervention, and recommendations for changes to better address cancer survivors' needs and basic study procedures.

    Time frame: post 8-week intervention

07

Study locations

1 site
  • UNC Chapel Hill Program on Integrative Medicine
    Chapel Hill, North Carolina 27599-7200, United States
08

References and documents

Individual participant data

Plan to share: No — No plan.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03196037
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
North Carolina Translational and Clinical Sciences Institute
Responsible party
Sponsor
First posted
Jun 22, 2017
Start date
Dec 5, 2017
Primary completion
Dec 7, 2018
Completion
Dec 7, 2018
Last update
Mar 7, 2019

Study contacts

Aaron T Piepmeier, PhD
study director · University of Rhode Island

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion